Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Adaptimmune Ther ADR
(NQ:
ADAP
)
1.110
-0.090 (-7.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Adaptimmune Ther ADR
< Previous
1
2
3
4
Next >
Why Adaptimmune Therapeutics Crushed the Market Today
May 20, 2021
A key pipeline drug performs well in a mid-stage clinical trial.
Via
The Motley Fool
38 Stocks Moving In Thursday's Mid-Day Session
May 20, 2021
Gainers Newegg Commerce Inc. (NASDAQ: NEGG) shares jumped 30% to $12.03. Precipio, Inc. (NASDAQ: PRPO) gained 22.3% to $5.05. Precipio recently announced it launched a new, four-...
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks
May 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) ESSA Pharma Inc. (NASDAQ:...
Via
Benzinga
Exposures
COVID-19
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
Exposures
Product Safety
20 Stocks Moving in Thursday's Pre-Market Session
May 20, 2021
Gainers PDS Biotechnology Corporation (NASDAQ: PDSB) rose 18% to $6.77 in pre-market trading as traders circulated abstract from American Society Of Clinical Oncology website....
Via
Benzinga
Adaptimmune's Stock Trades Higher As TCR Therapy Shows Initial Durability In Soft Tissue Cancer Settings
May 20, 2021
Adaptimmune Therapeutics plc (NASDAQ: ADAP) revealed initial data from its Phase 2 SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel...
Via
Benzinga
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows
May 11, 2021
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has reported first preclinical data from its HiT targeting mesothelin (a tumor-associated antigen), being co-...
Via
Benzinga
Earnings Outlook for Adaptimmune Therapeutics
May 05, 2021
On Thursday, May 06, Adaptimmune Therapeutics (NASDAQ:ADAP) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings...
Via
Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
May 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.